Mixture of fatty acids for use in the treatment of inflammatory pathologies

1. A mixture of nine fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid, wherein the palmitic acid, if present, is contained in said mixture in a quantity between 0.2% and 48% by weight; the oleic acid, if present, is contained in said mixture in a quantity between 0.2% and 38% by weight; the stearic acid, if present, is contained in said mixture in a quantity between 0.2% and 42% by weight; the linoleic acid, if present, is contained in said mixture in a quantity between 0.2% and 40% by weight; the alpha-linoleic acid, if present, is contained in said mixture in a quantity between 0.2% and 38% by weight; the gamma-linolenic acid, if present, is contained in said mixture in a quantity between 0.2% and 30% by weight; the eicosapentaenoic acid, if present, is contained in said mixture in a quantity between 0.2% and 25% by weight; the docosahexaenoic acid, if present, is contained in said mixture in a quantity between 0.2% and 25% by weight; the azelaic acid, if present, is contained in said mixture in a quantity between 0.2% and 40% by weight; and the myristic acid, if present, is contained in said mixture in a quantity between 0.005% and 0.01% by weight, with respect to the total weight of the mixture.

2. A pharmaceutical, cosmetic, and/or dietary composition comprising a mixture according to claim 1 , and at least one physiologically acceptable excipient.

3. A composition according to claim 2 , characterised in that the palmitic acid is contained in said composition in a quantity between 5% and 45% by weight; the oleic acid is contained in said composition in a quantity between 2% and 35% by weight; the stearic acid is contained in said composition in a quantity between 2% and 35% by weight; the linoleic acid is contained in said composition in a quantity between 1% and 40% by weight; the alpha-linolenic acid is contained in said composition in a quantity between 1% and 25% by weight; the gamma-linolenic acid is contained in said composition in a quantity between 0.5% and 10% by weight; the eicosapentaenoic acid is contained in said composition in a quantity between 1% and 20% by weight; the docosahexaenoic acid is contained in said composition in a quantity between 1% and 25% by weight; the azelaic acid is contained in said composition in a quantity between 0.5% and 10% by weight; the myristic acid is contained in said composition in a quantity between 0.05% and 1%, with respect to the total weight of the composition.

4. A composition according to claim 2 , formulated in oral, topical, rectal, vaginal, ophthalmic or parenteral form.

5. A composition according to claim 4 , characterised in that said oral form is selected from the group consisting of a tablet, capsule, granule, oily capsule, solution, suspension, carrier, and nebuliser solution.

6. A composition according to claim 4 , characterised in that said topical form is selected from the group consisting of a cream, ointment, gel, solution, suspension, spray, patch, and lyophilised granular powder.

7. A composition according to claim 4 , characterised in that said parenteral form is an aqueous buffer solution or an oily suspension.

8. A composition according to claim 4 , characterised in that said rectal form is a suppository, an enema, or a solution for endocavitary use.

9. A composition according to claim 4 , characterised in that said vaginal form is a pessary, a catheter, a gel, or a solution for endocavitary use.

10. A composition according to claim 4 , characterised in that said ophthalmic form is eyedrops, a wash, a cream, or an ointment.

11. A composition according to claim 2 , characterised in that the mixture is present in said composition in a quantity between 10% and 60% by weight.

12. The composition according to claim 11 , characterised in that the mixture is present in said composition in a quantity between 15% and 45% with respect to the total weight of the composition.

13. A composition according to claim 2 , characterised in that said composition is a dermocosmetic composition, a pharmaceutical substance, a dietary supplement, or a drug.

14. The composition according to claim 2 , wherein the at least one physiologically acceptable excipient is N-2-hydroxyethyl palmitamide.

15. A method of treating or preventing an inflammatory pathology in a human subject in need of therapy, comprising administering to a subject an effective amount of a pharmaceutical composition including a mixture of at least nine fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid mixture.

16. The method according to claim 15 , wherein the inflammatory pathology is in the acute or chronic phase.

17. The method according to claim 15 , wherein the inflammatory pathology include atopic dermatitis, dermatomyositis, scleroderma, psoriasis, polymyositis, pemphigus, or pemphigoid epidermolysis bullosa.

18. The method according to claim 15 , wherein the inflammatory pathology include Sjogren's syndrome, sympathetic ophthalmia, uveitis, or uveo-retinitis.

19. The method according to claim 15 , wherein the inflammatory pathology include mucosal pathologies, such as inflammation of the gastrointestinal mucous membranes (Crohn's disease) or inflammation of the oral and genital mucosa.

20. The method according to claim 15 , characterised in that said inflammatory pathologies include articular and connective pathologies such as rheumatoid arthritis, psoriatic arthritis, arthritis from lupus erythematosus, or discoid or systemic lupus erythematosus.

21. The method according to claim 15 , wherein the inflammatory pathology include chronic pathological inflammations, such as chronic solar dermatitis, asthma and intestinal and pulmonary fibrosis, or chronic arthritis.

22. The method according to claim 15 , wherein the inflammatory pathology include degenerative pathologies affecting the PNS and the CNS, such as multiple sclerosis, autoimmune neurodegenerative pathologies, non-autoimmune neurodegenerative pathologies, inflammatory processes connected to the CNS, such as Parkinson's disease, senile dementia, bacterial meningitis, HIV infection and traumatic injuries, or a pathology of the PNS, such as radiculopathy caused by inflammation.

23. The method according to claim 15 , wherein the inflammatory pathology is a pathology of the central and peripheral nervous system where the inflammatory processes follow the first ischemic insult, such as neuropathies due to compression, as well as traumatic neuropathies, cerebral strokes and cranial traumas.

24. The method according to claim 15 , wherein the inflammatory pathology is a cardiological disease deriving from perfusion phenomena as a consequence of ischemic injuries.

25. The method according to claim 15 , characterised in that said mixture and/or composition is administered daily, within a range of one to four doses a day.

26. The method according to claim 25 , characterised in that said mixture and/or composition is administered for at least four weeks.

27. The method according to claim 25 , characterised in that said dose contains from 0.1 to 50 mg of composition/kg of the patient's bodyweight.

28. The method according to claim 27 , characterised in that said dose contains from 0.5 to 20 mg/kg of the patient's bodyweight.

29. A method of treating or preventing an inflammatory pathology in a animal subject in need of therapy, comprising administering to a subject an effective amount of a pharmaceutical composition including a mixture of at least nine fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid.

30. The method according to claim 29 wherein the inflammatory pathology is used for treatment of neurogenic inflammations, articular and connective pathologies such as laminitis in horses, arthritis, respiratory pathologies, ophthalmic inflammation, keratoconjunctivitis sicca, and allergic inflammatory manifestations.

31. The method according to claim 29 wherein the inflammatory pathology is administered daily, within a range of one to four doses a day.

32. The method according to claim 29 wherein the inflammatory pathology is administered for at least four consecutive weeks.

33. The method according to claim 29 , wherein the inflammatory pathology wherein each of said doses contains from 0.1 to 50 mg of composition/kg of the animal's bodyweight.

34. The method according to claim 29 , wherein each of said doses contains 0.5 to 20 mg/kg of the animal's bodyweight.